A prospective, randomized trial to assess the cost impact of pharmacist- initiated interventions

Archives of Internal Medicine

Volumn 159, Issue 19, 1999, Pages 2306-2309

  McMullin, S Troy ^a   Hennenfent, Joel A ^a   Ritchie, David J ^a,b   Huey, Way Y ^a   Lonergan, Thomas P ^a   Schaiff, Robyn A ^a   Tonn, Michael E ^a   Bailey, Thomas C ^c  

^a BARNES JEWISH HOSPITAL   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

COST CONTROL; DRUG COSTS; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACISTS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 0032736868     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.19.2306     Document Type: Article

References (22)

1. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services: 1988-1995. Pharmacotherapy. 1996;16:1188-1208.
2. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr, Prato BS. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157:1689-1694.
3. Boyko WL, Yurkowski PJ, Ivey MF, Armistead JA, Roberts BL. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health Syst Pharm. 1997;54:15921-15925.
4. Suseno M, Tedeski L, Kent S, Rough S. Impact of documented pharmacists' interventions on patient care and cost. Hosp Pharm. 1998;33:676-681.
5. White MC, Chow MS. Cost impact and clinical benefit of focused rounding in the cardiovascular intensive care unit. Hosp Pharm. 1998;33:419-423.
6. Pauley TR, Magee MJ, Cury JD. Pharmacist-managed, physician-directed asthma management program reduces emergency department visits. Ann Pharmacother. 1995;29:5-9.
7. Bjornson DC, Hiner WO Jr, Potyk RP, et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993;50:1875-1884.
8. Britton ML, Lurvey PL. Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm. 1991;48:265-270.
9. Phillips SL, Carr-Lopez SM. Impact of a pharmacist on medication discontinuation in a hospital-based geriatric clinic. Am J Hosp Pharm. 1990;47:1075-1079.
10. Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother. 1993;27:555-559.
11. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997;17:271-276.
12. Anassi EO, Egbunike IG. Akpaffiong MJ, Ike EN, Cate TR. Developing and implementing guidelines to promote appropriate use of fluconazole therapy in an AIDS clinic. Hosp Pharm. 1988;29:576-578, 581-582, 585-586.
13. Briceland LL, Quintiliani R, Nightingale CH. Multidisciplinary cost-containment program promoting oral metronidazole for treatment of antibiotic-associated colitis. Am J Hosp Pharm. 1988;45:122-125.
14. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis. 1993;16:255-264.
15. Kirking DM, Svinte MK, Berardi RR, Cornish LA, Ryan ML. Evaluation of direct pharmacist intervention of conversion from parenteral to oral histamine H2-receptor antagonist therapy. Ann Pharmacother. 1991;25:80-84.
16. Dannenhoffer MA, Slaughter RL, Hunt SN. Use of concurrent monitoring and a preprinted note to modify prescribing of intravenous cimetidine and ranitidine therapy to oral therapy. Am J Hosp Pharm. 1989;46:1570-1575.
17. McEvoy GK, ed. American Hospital Formulary Service Drug Information. Bethesda, Md: American Society of Health-System Pharmacists Inc; 1998.
18. Iezzoni LI, Ash AS, Schwartz M, et al. Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes. Ann Intern Med. 1995;123:763-770.
19. Ehrenkranz NJ, Nerenberger DE, Slater KC, Shultz JM. Intervention to discontinue parenteral antimicrobial therapy in hospitalized patients with urinary tract infection, skin and soft tissue infection, or no evident infection. Infect Control Hosp Epidemiol. 1993;14:517-522.
20. Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy. 1997;17:277-281.
21. Dunagan WC, Medoff G. Formulary control of antimicrobial usage: what price freedom? Diagn Microbiol Infect Dis. 1993;16:265-274.
22. Woodward RS, Medoff G, Smith MD, Gray JL. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med. 1987;83:817-823.